Innate Pharma announces the full exercise of the greenshoe in the context of its initial public offering (IPO) on the Eurolist market (Compartment C) of Euronext Paris
Innate Pharma announces the success of its initial public offering (IPO) on the Eurolist market (Compartment C) of Euronext Paris
Innate Pharma SA announces the details of its initial public offering on the Eurolist market at Euronext Paris
Launch of Innate Pharma's IPO on Eurolist C by Euronext in Paris
Registration of French "Document de base" with the AMF
IPH 1201 enters in pre-clinical and pharmaceutical development
Encouraging data on IPH 1101 with final results from phase I clinical trial in solid tumours
Financial results for the first half of 2006
New TLR assets from Schering-Plough Corporation and advanced R&D collaboration with IGR
Strategic partnership with Novo Nordisk to research and develop drugs targeting NK
